Artiva (ARTV) CMO Subhashis Banerjee Exercises Options, Sells Shares

What Happened
Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics (ARTV), exercised 429 option shares and then sold the 429 resulting common shares. He paid $1.92 per share to exercise (total cost $824) and sold the shares in an open-market transaction at $12.00 each for total proceeds of $5,148 (net difference ≈ $4,324).

Key Details

• Transaction dates: August 18, 2026 (exercise and sale); Form 4 filed August 19, 2026.
• Exercise: 429 shares at $1.92 (total cash paid $824).
• Sale: 429 shares at $12.00 (total proceeds $5,148).
• Derivative entry: 429 option shares were marked disposed at $0.00, reflecting the option conversion/exercise.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — these trades occurred under a Rule 10b5-1 plan adopted May 14, 2026. F2 — the underlying option vests 25% on April 8, 2026, then monthly at 1/36th thereafter.
• Filing timeliness: filed the day after the transaction; no late filing indicated in the report.

Context
This is an exercise-and-sale sequence (common as a cashless exercise): the option was exercised and the resulting shares were sold the same day, converting vested option value into cash. The 10b5-1 plan note means the sale was made under a pre-established trading plan. As always, this is a factual disclosure of insider activity and should not be taken as a direct signal of company prospects.